Equity Overview
Price & Market Data
Price: $2.28
Daily Change: -$0.17 / 7.46%
Daily Range: $2.22 - $2.54
Market Cap: $3,480,740
Daily Volume: 140,621
Performance Metrics
1 Week: -52.50%
1 Month: -69.59%
3 Months: -76.00%
6 Months: -72.73%
1 Year: -82.06%
YTD: -84.00%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country:
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.